AJICAP-M uses Fc-affinity peptides to attach cancer drugs to antibodies at precise locations, producing more stable and consistent antibody-drug conjugates than traditional methods.
First continuous-flowAJICAP-M achieved the first site-selective ADC production using continuous-flow manufacturing
What the researchers found
AJICAP-M is a traceless site-selective conjugation method that uses Fc-affinity peptides to attach drugs to native (unmodified) antibodies at specific lysine residues (Lys248 or Lys288). The technology produces antibody-drug conjugates with:
- Consistent drug-to-antibody ratios
- Enhanced stability compared to traditional ADCs
- Superior in vivo stability demonstrated in comparative animal studies
- Compatibility with continuous-flow manufacturing — a first for site-selective ADC production
The "traceless" aspect means the affinity peptide is removed after conjugation, leaving no foreign material on the final product.
Why it matters
ADCs are one of the fastest-growing classes of cancer drugs, with over a dozen approved. Manufacturing consistency and stability remain major challenges. AJICAP-M's peptide-guided approach could make ADC production more reliable, potentially improving drug efficacy and reducing manufacturing costs.
How the study worked
The researchers developed Fc-affinity peptides that temporarily bind to antibodies and direct drug conjugation to specific lysine residues. After drug attachment, the peptide is removed. The resulting ADCs were characterized for drug-to-antibody ratio consistency and stability. In vivo experiments in animals compared AJICAP-M ADC stability to traditional ADCs. The technology was also demonstrated in continuous-flow manufacturing.
What this study cannot tell us
The abstract does not provide detailed comparative data on stability improvements or specific drug-to-antibody ratios achieved. Only two conjugation sites (Lys248, Lys288) were demonstrated. Clinical data with AJICAP-M-produced ADCs was not presented. The technology's compatibility with different antibody isotypes and drug payloads beyond those tested remains to be fully characterized.
How to read the evidence
This is a technology development paper published in Organic Letters demonstrating a novel conjugation chemistry with in vivo stability data. While rigorous as a chemistry study, the clinical relevance depends on future drug development using this technology.
When this study was published
Published in 2024 in Organic Letters, this is a recent advance in the rapidly evolving ADC manufacturing technology space.
The bigger picture
The ADC market is projected to exceed $30 billion by 2030. As more ADCs enter clinical development, manufacturing technologies that improve product consistency and stability become increasingly valuable. AJICAP-M's peptide-mediated approach represents a practical advancement that could be widely adopted across the pharmaceutical industry.
Questions still open
- How does AJICAP-M compare to other site-selective conjugation technologies in terms of cost and scalability?
- Are AJICAP-M-produced ADCs currently in clinical trials for any cancer indication?
- Could this affinity peptide approach be adapted for conjugating other payloads like radionuclides or immunostimulants?
Common questions
What are antibody-drug conjugates (ADCs)?
Why does it matter where the drug attaches to the antibody?
Read the original research
AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis.
Organic letters, 26(27), 5597-5601
Citation
Matsuda, Yutaka; Shikida, Natsuki; Hatada, Noriko; Yamada, Kei; Seki, Takuya; Nakahara, Yuichi; Endo, Yuta; Shimbo, Kazutaka; Takahashi, Kazutoshi; Nakayama, Akira; Mendelsohn, Brian A; Fujii, Tomohiro; Okuzumi, Tatsuya; Hirasawa, Shigeo. (2024). AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis.. Organic letters, 26(27), 5597-5601. https://doi.org/10.1021/acs.orglett.4c00878